Stay updated with breaking news from Camena Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Following its $10 million Series A financing in July 2023, Camena Bioscience has appointed Dr Nicola Thompson as Chair of its Board of Directors as part of plans for commercial expansion of its DNA synthesis platform, gSynth™. Click to read more...
Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, today announced it has appointed Dr Nicola Thompson as Chair of its Board of Directors.
23.11.2023 - 23 NOVEMBER 2023 NORTHERN 2 VCT PLC UNAUDITED HALF-YEARLY FINANCIAL REPORTFOR THE SIX MONTHS ENDED 30 SEPTEMBER 2023 Northern 2 VCT PLC is a Venture Capital Trust (VCT) managed by Mercia Fund Management Limited. It invests mainly in unquoted ...
/PRNewswire/ -- The "Oligonucleotide Synthesis Markets - Forecasts by Oligo Length, Application, and Product - With Executive and Consultant Guides. 2023 to...
Dublin, Oct. 05, 2023 (GLOBE NEWSWIRE) -- The